Evidence and research.

Every sourced item on this beat, newest first, each read for the roles it touches. Every weekday morning.

Announced2 sourcesFor patients and employeesThursday, November 5, 2026

Chief AI Officer CIO and CTO CMO (medical)

Google shares its framework for evaluating health AI at scale

Google published its framework for building safer and more helpful AI for health, describing how it evaluates health AI at scale. The same week, npj Digital Medicine published a cross-paradigm audit of large language model judges for clinical text evaluation.

Do this week. Compare Google's evaluation framework with how your team currently tests AI tools before go-live, and close the gaps you find. Run this

The claim.: Google says the framework is aimed at safer and more helpful health AI.
The evidence.: This is a company announcement; no independent evaluation of the framework exists yet.

For the Chief AI Officer. Use published vendor evaluation methods as a reference when writing your own acceptance criteria for clinical AI.

For the CIO and CTO. Ask vendors, including Google, which evaluation results they will share for the specific use you are buying.

For the Chief Medical Officer and physicians. Review whether automated LLM judges are part of any vendor's quality claims and ask how they were validated.

Disclosure at publication: Involves Google, a platform Ecofy tracks; editor to confirm any relationship.

Read the full item

Sources:Google Health blog npj Digital Medicine

Study2 sourcesFor patients and employeesMonday, November 2, 2026

Chief AI Officer CFO CMO (medical)COO

Medicare's AI-enabled prior authorization pilot linked to nearly 20% drop in some services

A research letter published Oct. 26 in JAMA found that in the first six months of Medicare's Wasteful and Inappropriate Service Reduction (WISeR) pilot, use of targeted services fell in participating states relative to the rest of the country. Researchers from the University of Minnesota School of Public Health and Brown University reported a drop of nearly 20% in some services, as covered by Becker's Hospital Review and Becker's Payer Issues.

Do this week. Pull your own volume and authorization data for WISeR-targeted services in participating states and compare it with the JAMA findings before your next payer review. Run this

The evidence.: The JAMA research letter, as reported by Becker's, links the pilot to a nearly 20% relative drop in use of some targeted services over its first six months.

For the Chief AI Officer. Brief the board that AI-enabled prior authorization now has a measured effect on service volume and add WISeR exposure to the AI risk register.

For the CFO and revenue cycle. Model the revenue effect of a relative volume drop on WISeR-targeted services in participating states and adjust forecasts.

For the Chief Medical Officer and physicians. Ask physician leaders to review whether care in targeted services is being delayed or forgone and document clinical rationale for appeals.

Read the full item

Sources:Becker's Hospital Review Becker's Payer Issues

Reported2 sourcesFor patientsMonday, November 2, 2026

Chief AI Officer CMO (marketing)Compliance Patient experience

Pew finds 46% of Americans oppose AI in insurance claim decisions

A Pew Research Center survey published Oct. 29 found nearly half of U.S. adults oppose AI playing any role in health insurance claim decisions, according to Becker's Payer Issues. The survey of 3,488 adults, conducted in June, tested openness to AI across eight healthcare tasks. Separately, Healthcare IT Today reported that 91% of patients want their permission required when AI is used for diagnosis.

Do this week. Review where your organization discloses AI use to patients and members, starting with claims and diagnosis, and close the gaps. Run this

The evidence.: The Pew survey of 3,488 adults, as reported by Becker's, found 46% oppose any AI role in claim decisions; no independent evidence ties disclosure practices to trust outcomes yet.

For the Chief AI Officer. Add patient disclosure and consent to the AI governance checklist for any tool touching claims or diagnosis.

For the Chief Marketing Officer. Prepare plain-language explanations of how AI is and is not used, so patients hear it from you rather than from a denial letter.

For the Compliance, privacy and legal. Inventory current consent language against AI use in diagnosis and claims and flag where permission is not sought.

For the Patient experience. Brief contact center staff on how to answer patient questions about AI in claims and care decisions.

Read the full item

Sources:Becker's Payer Issues Healthcare IT Today

Reported2 sourcesFor patients and employeesFriday, October 30, 2026

Chief AI Officer CMO (medical)CNO Compliance

Doximity research finds general AI models err on medication doses

Clinical AI company Doximity released research showing popular general-use AI models get medication doses wrong, some dangerously, and that its own dose verification tool performed better, Healthcare Dive reported. Separately, a family has sued OpenAI over ChatGPT advice on an epilepsy drug taper, Medical Economics reported.

Do this week. Issue clear guidance to clinicians on which AI tools are approved for dosing questions and require pharmacist or reference verification for any AI-suggested dose. Run this

The claim.: Doximity says its dose verification tool outperformed general-use models, which it describes as rife with errors.
The evidence.: The research comes from a vendor comparing its own product and has not been described as peer reviewed; the lawsuit is an allegation, not a finding.

For the Chief AI Officer. Confirm the approved-tools list covers dosing use cases and blocks or flags unapproved chatbots on clinical devices.

For the Chief Medical Officer and physicians. Remind prescribers that general chatbots are not dose references and route questions through verified sources.

For the CNO and nursing. Reinforce that nurses should not act on AI-generated dose information without the standard verification step.

For the Compliance, privacy and legal. Document the policy on clinician use of consumer AI so the organization can show reasonable controls.

Disclosure at publication: Ecofy orchestrates OpenAI for clients and says so on every item that names it. The item was selected and checked by the same rules as every other.

Read the full item

Sources:Healthcare Dive Medical Economics

Opinion4 sourcesFor patients and employeesWednesday, October 28, 2026

Chief AI Officer CMO (medical)Compliance

JAMA letters debate guardrails for advertising inside AI decision support tools

Letters in JAMA respond to a Singh and Mello Viewpoint warning that advertising in AI clinical decision support can influence care. One proposes a clinical query firewall; another compares free tools to past drug company giveaways. The authors reply that ending the practice altogether is unlikely.

Do this week. Inventory free or ad-supported AI decision support tools clinicians use and set a policy on which are permitted. Run this

The claim.: The letter writers argue commercial interests can shape medical judgment through ad-supported AI tools, and that clinical queries need protection.
The evidence.: These are opinion letters in JAMA; no study of patient impact is cited.

For the Chief AI Officer. Add ad-supported tools and query data use to AI vendor review criteria.

For the Chief Medical Officer and physicians. Ask physicians which free AI search tools they use and whether they show sponsored content.

For the Compliance, privacy and legal. Review whether clinician queries containing patient details flow to advertisers under tool terms.

Read the full item

Sources:JAMA JAMA JAMA JAMA

Opinion1 sourceFor patientsMonday, October 26, 2026

Chief AI Officer Patient experience CMO (marketing)

Researchers say long-term effects of chatbot use on isolation are unknown

In a STAT opinion piece, researchers argue that no one yet knows whether people gradually disconnect from one another over months of interacting with chatbots, and that researchers need better access to data to find out.

Do this week. Review any patient-facing chatbot you run or plan to run and add a clear handoff to a human and a way to measure repeat use. Run this

The claim.: The authors argue that cumulative chatbot use may affect social connection and that the data to study it is missing.
The evidence.: This is an opinion piece; the authors state that the evidence does not yet exist.

For the Chief AI Officer. Add usage and escalation monitoring to the governance requirements for patient-facing AI.

For the Patient experience. Make sure frequent chatbot users are offered contact with a person, especially in behavioral health and senior care.

Read the full item

Sources:STAT Health Tech

Study1 sourceFor employees and patientsSunday, October 25, 2026

Chief AI Officer CMO (medical)CFO CIO and CTO

Jefferson Health ambient AI users closed charts up to 39% faster

A study published Oct. 23 in NEJM Catalyst Innovations in Care Delivery covered 5,234 Jefferson Health clinicians with access to Abridge's ambient documentation tool, Becker's reports. The rollout was associated with up to 16.6% less after-hours documentation and up to 39.3% faster chart closure among the most active users.

Do this week. Set after-hours documentation time and chart closure speed, segmented by usage level, as the scorecard for your own ambient AI pilot or renewal. Run this

The claim.: The authors associate the gains with ambient AI use, concentrated among the most active users.
The evidence.: NEJM Catalyst Innovations in Care Delivery, as reported by Becker's, reports associations rather than a controlled trial, and the largest gains are limited to the heaviest users.

For the Chief Medical Officer and physicians. Ask your ambient AI vendor for chart closure and after-hours time by user tier so you can see whether low adopters need coaching or a different tool.

Read the full item

Sources:Becker's Hospital Review